BioStorage Technologies Expands U.S. Operations with Opening of New Biorepository Facility
INDIANAPOLIS, May 26, 2011 /PRNewswire/ -- BioStorage Technologies, the premier global provider of comprehensive sample management solutions, announced today that it has opened its new state-of-the-art biorepository facility in Indianapolis. The 60,000-square-foot facility is part of the company's strategic growth plan, and represents a 4.6MM investment by BioStorage Technologies.
Strategically placed near the second largest FedEx hub in the United States, the new facility is dedicated to the preparation, storage and cold-chain transport of human biological samples for a wide variety of customers, including academic centers, contract research organizations, donor programs and biotechnology companies. BioStorage Technologies is continuing to employ a growing number of sample management experts, making it one of the largest and most technology-driven biorepositories in the world.
"BioStorage Technologies is committed to its investment in comprehensive sample management solutions, and this new facility provides the company with the infrastructure needed to support our continued growth and expanded services," said Greg Swanberg, CEO of BioStorage Technologies.
The facility expansion has provided BioStorage Technologies the ability to offer sample preparation services, including automated liquid handling technology to ensure the accuracy and precision needed for high-throughput DNA and RNA extraction and verification.
The integration of these services allows BioStorage Technologies to provide customers with a sample renewal and extension process to maximize their samples for comprehensive research and development activities. Once samples are processed, aliquots of blood and/or DNA products can be retrieved and scheduled for transport to research testing sites through the company's proprietary tracking and inventory management system, ISISS®. This process ensures samples are removed, transported, processed and replaced to storage in a compliant, consistent and efficient fashion.
"The future of drug discovery is in personalized medicine and genomic-based therapies, which will require an ability to store and analyze large quantities of tissue and blood samples," added Swanberg. "As this trend continues, an increasing amount of pharma and biotech companies rely on our expertise in comprehensive sample management to ensure their valuable biological samples are managed in optimal conditions and not jeopardized by pre-analytical variables that can have a negative impact on sample integrity."
The new biorepository facility offers a wide range of storage options, including automated carousel controlled-room temperature storage at 15 degrees C to 27 degrees C, bulk sample storage at 15 degrees C to 27 degrees C, walk-in cold sample storage -20 degrees C to 5 degrees C, ultra-low temperature storage -70 degrees C to -80 degrees C, and -190 degrees C vapor phase liquid nitrogen. In addition, BioStorage Technologies maintains FDA 21 CFR Part 11 validated technology systems and adheres to U.S. Food and Drug Administration regulations, as well as U.S. Department of Transportation and International Air Transport Association guidelines.
About BioStorage Technologies, Inc.:
BioStorage Technologies Inc. is the premier global provider of comprehensive sample management and onsite solutions for the bioscience industry. Offering a team of sample management experts, state-of-the-art temperature-controlled storage facilities, a real-time, web-based sample intelligence and tracking, BioStorage Technologies manages the complete life-cycle of sample assets enabling companies to maximize opportunities, minimize risk and reduce costs. BioStorage Technologies, Inc. is privately held and headquartered in Indianapolis with an additional full-service site near Frankfurt, Germany. For more information, visit www.biostorage.com or call +1 (866) 697-2675 or +49-6155-898-1011.
Press Contact:Michael Clark Miller Brooks, Inc.email@example.com
SOURCE BioStorage Technologies